Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

Tekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.

Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”

Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.

Go Back

Share this story

Comments


Related articles


Parkinson's productive

Interviews

“Fear prevents people from living a productive life”

The latest in our monthly series profiling WPC2019 bloggers

READ MORE

Resources & Tools

VIDEO: Parkinson’s stem cell treatments explained in just 90 seconds

Watch Professor Roger Barker explain new stem cell treatments

READ MORE
80417_PL_Tim Hague Sr lead

Perspectives

World Parkinson Congress 2019 Bloggers: Tim Hague

#WPC2019: We talk to Canadian blogger Tim Hague Sr

READ MORE